Standardization of Coagulation Factor V Reference Intervals, Prothrombin Time, and Activated Partial Thromboplastin Time in Mice for Use in Factor V Deficiency Pathological Models

被引:3
|
作者
De Pablo-Moreno, Juan A. [1 ]
Liras, Antonio [1 ]
Revuelta, Luis [2 ]
机构
[1] Univ Complutense Madrid, Sch Biol, Dept Genet Physiol & Microbiol, Madrid, Spain
[2] Univ Complutense Madrid, Sch Vet Med, Dept Physiol, Madrid, Spain
关键词
factor V; prothrombin time; activated partial thromboplastin time; mouse; measurement standardization; transfusion; pathological models; factor V deficiency; HEMOPHILIA-A; PLASMA; TRANSFUSION; HEMORRHAGE; EVOLUTION; SELECTION;
D O I
10.3389/fvets.2022.846216
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Factor V together with activated factor X forms the prothrombinase complex, which transforms prothrombin into thrombin. The Mus musculus species is characterized by very high levels of this factor and short clotting times, which hinders accurate measurements. For that reason, a detailed characterization of such parameters is indispensable. A method was designed as part of this study to provide an accurate determination and standardization of factor V levels, prothrombin time and activated partial thromboplastin time in Mus musculus. Those parameters were evaluated in a sample of 66 healthy animals using a semi-automated coagulometer and human diagnostic reagents in an attempt to determine the most appropriate time of day for the extractions. A mouse-based protocol was designed, capable of making corrections to the samples at dilutions of 1:100 for factor V and at of 1:3 for prothrombin time. The goal was to smoothen the calibration curves, which often present with steep slopes and narrow measurement ranges between one calibration point and another. It was found that the most stable period for blood sample extraction was that comprised between the first 6 h of light. No clinical differences were observed between the sexes and reference intervals were established for factor V (95.80% +/- 18.14; 25.21 s +/- 1.34), prothrombin time (104.31% +/- 14.52; 16.85 s +/- 1.32) and activated partial thromboplastin time (32.86 s +/- 3.01). The results obtained are applicable to human or veterinary biomedical research, to transfusional medicine or to pathological models for diseases such as factor V deficiency.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests
    Adcock, D. M.
    Moore, G. W.
    Kershaw, G. W.
    Montalvao, S. A. L.
    Gosselin, R. C.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2024, 46 (05) : 777 - 788
  • [42] Variability in international normalized ratio and activated partial thromboplastin time after injury are not explained by coagulation factor deficits
    Stettler, Gregory R.
    Moore, Ernest E.
    Moore, Hunter B.
    Nunns, Geoffrey R.
    Coleman, Julia R.
    Colvis, Arthur
    Ghasabyan, Arsen
    Cohen, Mitchell J.
    Silliman, Christopher C.
    Banerjee, Anirban
    Sauaia, Angela
    JOURNAL OF TRAUMA AND ACUTE CARE SURGERY, 2019, 87 (03): : 582 - 589
  • [43] Evaluation of activated partial thromboplastin time coagulation waveform analysis for identification of patients with acquired factor VIII inhibitors
    McGinnis, Eric
    Wong, Steven K. W.
    Smith, Tyler W.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2020, 42 (04) : 411 - 417
  • [44] Comparison of an activated partial thromboplastin time with a Russell viper venom time test in screening for factor V-Leiden (FVR506Q)
    Sweeney, JD
    Blair, AJ
    King, TC
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1997, 108 (01) : 74 - 77
  • [45] Prothrombin Time, Activated Partial Thromboplastin Time, Fibrinogen, and D-dimer as a Predictor of Decompensated Disseminated Intravascular Coagulation in Sepsis
    Fenny
    Dalimoenthe, Nadjwa Zamalek
    Noormartany
    Pranggono, Emmy
    Dewi, Nina Susana
    MAJALAH KEDOKTERAN BANDUNG-MKB-BANDUNG MEDICAL JOURNAL, 2011, 43 (01): : 49 - 54
  • [46] Clinical Use of the Activated Partial Thromboplastin Time and Prothrombin Time for Screening A Review of the Literature and Current Guidelines for Testing
    Levy, Jerrold H.
    Szlam, Fania
    Wolberg, Alisa S.
    Winkler, Anne
    CLINICS IN LABORATORY MEDICINE, 2014, 34 (03) : 453 - +
  • [47] The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency
    González-Boullosa, R
    Ocampo-Martínez, R
    Alarcón-Martín, MJ
    Suárez-Rodríguez, M
    Domínguez-Viguera, L
    González-Fajo, G
    HAEMOPHILIA, 2005, 11 (02) : 167 - 170
  • [48] A COMPARISON OF 2 ACTIVATED PARTIAL THROMBOPLASTIN TIME REAGENTS FOR ROUTINE COAGULATION LABORATORY USE
    RAY, MJ
    HAWSON, GAT
    THROMBOSIS AND HAEMOSTASIS, 1989, 62 (01) : 144 - 144
  • [49] Laboratory Measurements of the Oral Direct Factor Xa Inhibitor Edoxaban Comparison of Prothrombin Time, Activated Partial Thromboplastin Time, and Thrombin Generation Assay
    Morishima, Yoshiyuki
    Kamisato, Chikako
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 143 (02) : 241 - 247
  • [50] THE ACTIVATED PARTIAL THROMBOPLASTIN TIME .2. CLOTTING-FACTOR INHIBITORS
    CALLAHAN, JB
    GODWIN, J
    EMERGENCY MEDICINE, 1986, 18 (18) : 85 - &